Imugene Annual Update 2016; Clinical Sites in Asia Opened & New Substantial Shareholder

Imugene Ltd (ASX: IMU) is an immuno-oncology focused biopharmaceutical company, developing HER-Vaxx, a B Cell peptide vaccine for the treatment of gastric cancer. In no order of importance are listed Imugene’s achievements of 2016;

  • A successful capital raising, in doing so bringing on a substantial shareholder in The Platinum Asset Management Fund.
  • Opened our clinical sites in Asia and we look forward to enrolling the first cohort of patients.
  • Progressed our mimotope discovery platform with the filing of four important patents.

Imugene are proud to have maintained and strengthened their already strong international intellectual property position. Also mentioning the progress made by their scientific team, both at home and abroad in Vienna.